DE69905489D1 - Protein c zur behandlung von sichelzellanämie und thalassämie - Google Patents
Protein c zur behandlung von sichelzellanämie und thalassämieInfo
- Publication number
- DE69905489D1 DE69905489D1 DE69905489T DE69905489T DE69905489D1 DE 69905489 D1 DE69905489 D1 DE 69905489D1 DE 69905489 T DE69905489 T DE 69905489T DE 69905489 T DE69905489 T DE 69905489T DE 69905489 D1 DE69905489 D1 DE 69905489D1
- Authority
- DE
- Germany
- Prior art keywords
- thalassemia
- protein
- treatment
- sickle
- lemenia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000002903 Thalassemia Diseases 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 208000007056 sickle cell anemia Diseases 0.000 abstract 2
- 206010062713 Haemorrhagic diathesis Diseases 0.000 abstract 1
- 101800004937 Protein C Proteins 0.000 abstract 1
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 abstract 1
- 101800001700 Saposin-D Proteins 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 229940127090 anticoagulant agent Drugs 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000031169 hemorrhagic disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229960000856 protein c Drugs 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4866—Protein C (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10947498P | 1998-11-23 | 1998-11-23 | |
| PCT/US1999/026958 WO2000030676A1 (en) | 1998-11-23 | 1999-11-16 | Method of treating sickle cell disease and thalassemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69905489D1 true DE69905489D1 (de) | 2003-03-27 |
| DE69905489T2 DE69905489T2 (de) | 2003-09-11 |
Family
ID=22327841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69905489T Expired - Lifetime DE69905489T2 (de) | 1998-11-23 | 1999-11-16 | Protein c zur behandlung von sichelzellanämie und thalassämie |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6372213B2 (de) |
| EP (1) | EP1133314B1 (de) |
| JP (1) | JP2002530352A (de) |
| CN (1) | CN1326357A (de) |
| AT (1) | ATE232739T1 (de) |
| AU (1) | AU1723200A (de) |
| BR (1) | BR9915572A (de) |
| CA (1) | CA2351591A1 (de) |
| DE (1) | DE69905489T2 (de) |
| DK (1) | DK1133314T3 (de) |
| ES (1) | ES2192874T3 (de) |
| IL (1) | IL142247A0 (de) |
| WO (1) | WO2000030676A1 (de) |
| ZA (1) | ZA200102727B (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002024215A2 (en) * | 2000-09-18 | 2002-03-28 | Eli Lilly And Company | Method for using activated protein c for the treatment of coagulation-associated disorders |
| US20060246161A1 (en) * | 2003-02-21 | 2006-11-02 | Hongtao Xing | Method of making medicament for treating anemia |
| EP2815749A1 (de) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Feste Form von 4-Amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dion mit spezifischem Röntgenbeugungsspektrum |
| WO2018013693A1 (en) | 2016-07-13 | 2018-01-18 | Celgene Corporation | Solid dispersions and cocrystals comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione compositions and methods of use thereof |
| WO2018013689A1 (en) | 2016-07-13 | 2018-01-18 | Celgene Corporation | Solid dispersions and solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, method of preparation and use thereof |
| CN106399478B (zh) | 2016-08-31 | 2024-09-03 | 桂林优利特医疗电子有限公司 | 一种荧光探针PCR法快速检测α/β-地中海贫血的试剂盒 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4775624A (en) | 1985-02-08 | 1988-10-04 | Eli Lilly And Company | Vectors and compounds for expression of human protein C |
| US5516650A (en) | 1985-06-27 | 1996-05-14 | Zymogenetics, Inc. | Production of activated protein C |
| US5550036A (en) | 1986-04-09 | 1996-08-27 | Eli Lilly And Company | Method for co-amplification of human protein C genes in human cells |
| US5084274A (en) | 1987-11-17 | 1992-01-28 | Scripps Clinic And Research Foundation | Inhibition of arterial thrombotic occlusion or thromboembolism |
| US4992373A (en) | 1987-12-04 | 1991-02-12 | Eli Lilly And Company | Vectors and compounds for direct expression of activated human protein C |
| GB8819607D0 (en) | 1988-08-17 | 1988-09-21 | Wellcome Found | Novel combination |
| US4981952A (en) | 1988-10-04 | 1991-01-01 | Eli Lilly And Company | Method for the purification of vitamin K-dependent proteins |
| IL97312A (en) | 1990-02-23 | 1999-01-26 | Lilly Co Eli | A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient |
| AT402262B (de) | 1991-06-20 | 1997-03-25 | Immuno Ag | Arzneimittel enthaltend aktiviertes protein c |
| MY110664A (en) | 1992-05-21 | 1999-01-30 | Lilly Co Eli | Protein c derivatives |
| WO1997020043A1 (en) | 1995-11-30 | 1997-06-05 | Zymogenetics, Inc. | Protein c production in transgenic animals |
| AR015598A1 (es) * | 1997-04-28 | 2001-05-16 | Lilly Co Eli | FORMULACIoN LIOFILIZADA QUE COMPRENDE PROTEíNA C ACTIVADA, SU USO PARA LA PREPARACIoN DE UN MEDICAMENTO Y FORMA DE DOSIS UNITARIA QUE LA COMPRENDE. |
| HUP0001237A3 (en) * | 1997-10-20 | 2002-01-28 | Lilly Co Eli | Methods for treating vascular disorders |
-
1999
- 1999-11-16 AT AT99960334T patent/ATE232739T1/de not_active IP Right Cessation
- 1999-11-16 DE DE69905489T patent/DE69905489T2/de not_active Expired - Lifetime
- 1999-11-16 IL IL14224799A patent/IL142247A0/xx unknown
- 1999-11-16 JP JP2000583559A patent/JP2002530352A/ja not_active Withdrawn
- 1999-11-16 ES ES99960334T patent/ES2192874T3/es not_active Expired - Lifetime
- 1999-11-16 EP EP99960334A patent/EP1133314B1/de not_active Expired - Lifetime
- 1999-11-16 CN CN99813350A patent/CN1326357A/zh active Pending
- 1999-11-16 WO PCT/US1999/026958 patent/WO2000030676A1/en not_active Ceased
- 1999-11-16 CA CA002351591A patent/CA2351591A1/en not_active Abandoned
- 1999-11-16 DK DK99960334T patent/DK1133314T3/da active
- 1999-11-16 AU AU17232/00A patent/AU1723200A/en not_active Abandoned
- 1999-11-16 BR BR9915572-9A patent/BR9915572A/pt not_active Application Discontinuation
- 1999-11-22 US US09/444,746 patent/US6372213B2/en not_active Expired - Fee Related
-
2001
- 2001-04-03 ZA ZA200102727A patent/ZA200102727B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2351591A1 (en) | 2000-06-02 |
| BR9915572A (pt) | 2001-08-14 |
| DE69905489T2 (de) | 2003-09-11 |
| ES2192874T3 (es) | 2003-10-16 |
| EP1133314B1 (de) | 2003-02-19 |
| IL142247A0 (en) | 2002-03-10 |
| CN1326357A (zh) | 2001-12-12 |
| US20020012662A1 (en) | 2002-01-31 |
| WO2000030676A1 (en) | 2000-06-02 |
| ZA200102727B (en) | 2002-09-25 |
| ATE232739T1 (de) | 2003-03-15 |
| AU1723200A (en) | 2000-06-13 |
| EP1133314A1 (de) | 2001-09-19 |
| DK1133314T3 (da) | 2003-04-14 |
| JP2002530352A (ja) | 2002-09-17 |
| US6372213B2 (en) | 2002-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69200675D1 (de) | Verwendung von Droloxifen bei der Behandlung von Knochenerkrankungen. | |
| DE69508192D1 (de) | Wasserlösliches nimesulid-salz, sowie dessen verwendung zur behandlung von entzündungen | |
| DE69521620D1 (de) | Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom | |
| IS4226A (is) | Hliðstæðar aðferðir við framleiðslu á nýjum (R)-5-karbamóýl-8-flúor-3-N,N-tvíútskiptum-amínó-3,4-díhýdró-2H-1-bensópýrönum | |
| DE69941586D1 (de) | Verwendung von Uridin in Kombination mit Cholin zur Behandlung von Gedächtnisstörungen | |
| ATE296634T1 (de) | (s,s)-reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen | |
| ATE311226T1 (de) | Die glycin-betain für seine antithrombotische verwendung | |
| DE60141636D1 (de) | Phospholipidderivate von valproinsäure und ihre kombinationen | |
| BG100930A (bg) | Фармацевтични състави и лекарствени средства за профилактика и лечение на ендотелиални нарушения | |
| RU95111308A (ru) | Производные 2-амино-4-фенил-4-оксомасляной кислоты, способы получения, фармацевтическая композиция | |
| NO20014241D0 (no) | C16-umettede FP-selektive prostaglandinanaloger | |
| ATE235915T1 (de) | Behandlung von hämorrhagischem virusfieber mit protein c | |
| DE69905489D1 (de) | Protein c zur behandlung von sichelzellanämie und thalassämie | |
| ATE225171T1 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
| ATE192923T1 (de) | Verwendung von boswelliasäure zur behandlung von hirntumoren | |
| DE69735417D1 (de) | 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen | |
| ATE218856T1 (de) | Aminotetralinderivat zur behandlung von herzkreislauferkrankung | |
| DE50111407D1 (de) | Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen | |
| WO1999058098A8 (en) | HUMAN ANTITHROMBIN IIIs AND METHODS RELATED THERETO | |
| ATA77095A (de) | Stabiles präparat zur behandlung von blutgerinnungsstörungen, enthaltend eine aktive gerinnungsfördernde stubstanz | |
| DE69930419D1 (de) | Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie | |
| ATE357914T1 (de) | Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien | |
| DE68913995D1 (de) | Zusammensetzung zur behandlung progressiver myopie. | |
| ATE311901T1 (de) | Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten | |
| ATE258550T1 (de) | Oxirancarbonsäuren für die behandlung von diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: CARDIOME PHARMA CORP., VANCOUVER, CA |
|
| 8328 | Change in the person/name/address of the agent |
Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336 |
|
| 8328 | Change in the person/name/address of the agent |
Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN |